Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,599.00
Bid: 1,594.50
Ask: 1,595.50
Change: -19.00 (-1.17%)
Spread: 1.00 (0.063%)
Open: 1,608.00
High: 1,615.00
Low: 1,575.00
Prev. Close: 1,618.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

RPT-FEATURE-As smokers spark up e-cigs to quit, traditional aids suffer

Thu, 29th Jan 2015 06:00

(Repeats with no changes to text)

By Jilian Mincer

NEW YORK, Jan 29 (Reuters) - When Marty Weinstein decided toquit smoking, he took a friend's advice and tried electroniccigarettes rather than government-approved nicotine replacementproducts.

Weinstein, 58, has gone from a pack a day nine months ago tothe equivalent in nicotine of four or five cigarettes. Thee-cigs have a familiar look and feel, and quench his desire tohold on to a cigarette and puff.

"I fully understand I'm still addicted to nicotine," saidWeinstein, a Connecticut taxi driver who had smoked for morethan 20 years. "But I'm now so much healthier."

E-cigarettes, metal tubes that heat liquids typically lacedwith nicotine and deliver vapor when sucked, are transformingthe market for smoking cessation products and slowing the $2.4billion in global sales of long-standing aids such as nicotinepatches and gums. But their impact on health remains unclear,experts say, raising difficult questions for regulators who arestarting to impose limits on e-cigarette use.

E-cigarette makers in the United States are barred fromexplicitly marketing the products as smoking cessation devices,but have found ways to appeal legally to smokers who arethinking of quitting.

"You never say 'quit' because it's not approved by the FDAas a smoking cessation device," said Jose Castro, the chiefexecutive of A1 Vapors in Miami, referring to the U.S. Food andDrug Administration.

A1 Vapors runs an ad on its website urging customers to"kiss tobacco goodbye" and give themselves the "gift of yourlife. literally", adding a disclaimer that e-cigs are not asmoking cessation product.

E-cigarettes, or e-cigs, have only come into widespread usein the past few years, but have already made inroads intotraditional quitting therapies.

About a third of British smokers trying to quit were usinge-cigarettes, according to a University College London survey inJanuary of 1,800 people, including 450 smokers.

E-cigs are used by almost twice as many people asgovernment-approved nicotine gums, lozenges and patches,according to the survey. That was a reversal from 2011, whenonly about 5 percent of people were using e-cigarettes and morethan 30 percent used over-the-counter products.

Similar data is not yet publicly available for the UnitedStates.

Worldwide sales of all nicotine replacement therapies grewjust 1.2 percent last year, to almost $2.4 billion, according todata from commercial researcher Euromonitor. U.S. sales, at $900million, grew 0.2 percent, and are expected by Euromonitor todrop this year by that amount.

Big tobacco companies like Altria, Lorillard and Reynolds American have rushed into the e-cig market.The entire U.S. market for "vapor devices" such as e-cigs grewin 2014 by 40-50 percent to $2.5 billion to $3 billion,Euromonitor said. The global market is worth $5 billion.

RULES ON E-CIGS TIGHTENING

Mark Strobel, a consumer health analyst at Euromonitor, saide-cigarettes have slowed nicotine replacement therapy sales,along with relatively high prices and a shrinking population ofsmokers, especially in the United States.

"For some consumers it has been a direct substitution."

GlaxoSmithKline (GSK) and Johnson & Johnson don't break out the data on their smoking cessation products,which are relatively small parts of their sales, but thecompanies have noted the change.

"It's definitely taken a bit of our market, no question atall - but there's a lot of competition in that space," GSK chiefexecutive Andrew Witty told Reuters in an interview this month.

GSK's nicotine replacement therapies and smoking cessationproducts include the brands Nicorette, NicoDermCQ and themedicine Zyban.

There is little long-term safety data on e-cigarettes,although some healthcare professionals say they may be betterfor consumers than tobacco cigarettes because they have nocarbon monoxide and fewer cancer-causing chemicals.

A growing number of states, cities and countries - includingIsrael and Australia - are considering or have approvedlegislation to ban or limit the devices or the liquids, whichcome in exotic flavors from bacon to bubble gum.

California's top public health official on Wednesday slammede-cigs as addictive, saying they were leading to nicotinepoisoning among children and threatened to unravel the state'sdecades-long effort to reduce tobacco use.

Earlier this week, California introduced a bill that wouldban the devices in public places, and New York Gov. Andrew Cuomoproposed a similar ban earlier this month.

Last year, the World Health Organization recommended thatsmokers should be encouraged to try already approved treatmentsrather than e-cigarettes. The FDA last April proposed rules forelectronic cigarettes that would, among other things, ban salesto those under 18, but not restrict flavored products, onlinesales or advertising.

MAKING SMOKING COOL AGAIN?

Many health experts worry that e-cigarettes will becomeestablished as smoking cessation aids before enough research isdone to determine their health impact. Another concern is thatthey may stop people from quitting tobacco completely and deterpeople from trying potentially more effective methods.

Dr. Albert Rizzo, senior medical advisor for the AmericanLung Association, said that when patients ask about theproducts, he tells them it's good that they are trying to quitbut: "We don't know enough to recommend them."

Some healthcare professionals said that even if they are notopposed to e-cigarettes, they are concerned about theirmarketing, especially to young people.

The Federal Trade Commission declined to comment on specifice-cig ads but said "advertising must be truthful, non-deceptiveand supported by competent and reliable scientific evidence."

E-cigs risk bringing the "cool" back to smoking, reversingthe progress over decades in which smoking has become lesssocially acceptable, said Dr. Robert K. Jackler, a professor atStanford University School of Medicine.

"A lot of us are very concerned about the renormalizationphenomenon," he said. "These glamorize smoking behavior."

Still, some doctors point to the low efficacy of traditionalways to quit smoking.

"They have better results than placebos, but their rates ofsuccess are quite low," said Dr. Michael Siegel, a professor atthe Boston University School of Public Health, who saide-cigarettes are an alternative, especially for people who havetried the conventional therapies and failed. (Additional reporting by Kate C. Kelland and Ben Hirschler inLondon; editing by Peter Henderson and Stuart Grudgings)

More News
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more
20 Feb 2024 15:10

PRESS: AJ Bell founder to join Applied Nutrition ahead of IPO - Sky

(Alliance News) - Supplements maker Applied Nutrition, plotting a London stock market float, is to add AJ Bell PLC founder Andy Bell as its chair, Sky News reported on Tuesday.

Read more
20 Feb 2024 08:55

IN BRIEF: Diageo welcomes GSK's CFO as non-executive director

Diageo PLC - London-based brewer and distiller sells more than 200 drinks brands, including Guinness stout, Captain Morgan rum and Johnnie Walker whisky - Appoints GSK PLC's chief financial officer and executive director, Julie Brown, as a non-executive director. Says she will succeed Alan Stewart as chair of the audit committee after his retirement following the firm's annual general meeting in September. Chair Javier Ferran says: "Julie brings many years of experience in financial, commercial and strategic roles in international companies operating in highly regulated industries. She is strongly committed to enabling diversity in business and to creating sustainable, long-term value for stakeholders. I look forward to her contribution to Board discussions and to working with her in progressing Diageo's ambition to be one of the most trusted and respected consumer products companies in the world."

Read more
15 Feb 2024 14:44

UK dividends calendar - next 7 days

Friday 16 February 
JPMorgan Asia Growth & Income PLCdividend payment date
JPMorgan Japan Small Cap Growth & Income PLCdividend payment date
Murray International Trust PLCdividend payment date
Premier Miton Group PLCdividend payment date
Schroder Oriental Income Funddividend payment date
Solid State PLCdividend payment date
Monday 19 February 
no events scheduled 
Tuesday 20 February 
Invesco Bond Income Plus Ltd 
Wednesday 21 February 
no events scheduled 
Thursday 22 February 
abrdn Asia Focus PLCex-dividend payment date
Alumasc Group PLCex-dividend payment date
AstraZeneca PLCex-dividend payment date
BlackRock Throgmorton Trust PLCex-dividend payment date
Braemar PLCex-dividend payment date
easyJet PLCex-dividend payment date
Ecofin US Renewables Infrastructure Trust PLCex-dividend payment date
Endeavour Mining PLCex-dividend payment date
FRP Advisory Group PLCex-dividend payment date
Gateley Holdings PLCex-dividend payment date
GSK PLCex-dividend payment date
Hercules Site Services PLCex-dividend payment date
Jersey Electricity PLCex-dividend payment date
Land Securities Group PLCex-dividend payment date
Molten Ventures VCT PLCex-dividend payment date
Northern Bear PLCex-dividend payment date
Redrow PLCex-dividend payment date
Samuel Heath & Sons PLCex-dividend payment date
Titon Holdings PLCex-dividend payment date
Unilever PLCex-dividend payment date
Van Elle Holdings PLCex-dividend payment date
Virgin Money UK PLCex-dividend payment date
Witan Investment Trust PLCex-dividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
15 Feb 2024 11:02

Berenberg hikes target price on GSK

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker GSK from £16.50 to £18.20 on Thursday, stating the group was moving closer to offsetting losses associated with the expiry of its patent on HIV drug dolutegravir.

Read more
15 Feb 2024 09:45

LONDON BROKER RATINGS: Jefferies cuts Kingfisher but Citi raises

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
15 Feb 2024 08:49

GSK completes USD1.4 billion purchase of respiratory firm Aiolos Bio

(Alliance News) - GSK PLC on Thursday said it has completed the acquisition of Aiolos Bio Ltd, expanding its respiratory portfolio with a potential "best-in-class" asthma treatment.

Read more
13 Feb 2024 16:53

LONDON MARKET CLOSE: Stocks in red amid sticky US inflation data

(Alliance News) - Stock prices in London closed in the red on Tuesday, after a key US inflation reading came in hotter-than-expected.

Read more
13 Feb 2024 16:21

London close: Stocks fall as US inflation tops expectations

(Sharecast News) - London markets ended the trading day in negative territory on Tuesday, influenced by concerns over higher inflation figures from the United States and a deceleration in wage growth within the UK.

Read more
13 Feb 2024 16:21

London close: Stocks fall as US inflation tops expectations

(Sharecast News) - London markets ended the trading day in negative territory on Tuesday, influenced by concerns over higher inflation figures from the United States and a deceleration in wage growth within the UK.

Read more
13 Feb 2024 12:06

LONDON MARKET MIDDAY: Stocks fall but pound up before US data

(Alliance News) - Stock prices in London were on the decline on Tuesday afternoon, with sentiment tetchy ahead of a US inflation report later.

Read more
13 Feb 2024 09:45

Citi ups recommendation on GSK to 'buy'

(Sharecast News) - Citi has upgraded its rating on vaccines and drugs blue chip GSK to 'buy' while also boosting its earnings estimates.

Read more
13 Feb 2024 09:32

LONDON BROKER RATINGS: Citi lifts GSK; Shore likes XPS Pensions

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
13 Feb 2024 07:45

LONDON BRIEFING: "Record" Tui quarter; Ultimate Products eyes payouts

(Alliance News) - London's FTSE 100 is to open ever-so-slightly lower on Tuesday, with trade set to be nervy ahead of the afternoon's US inflation data.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.